BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer

Dequina A. Nicholas; Guillaume Andrieu; Katherine J. Strissel; Barbara S. Nikolajczyk; Gerald V. Denis

doi:10.1007/s00018-016-2320-0

BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer

Dequina A. Nicholas, Guillaume Andrieu, Katherine J. Strissel, Barbara S. Nikolajczyk, Gerald V. Denis

Research output: Contribution to journal › Review article › peer-review

20 Scopus citations

Abstract

Chronic inflammation drives pathologies associated with type 2 diabetes (T2D) and breast cancer. Obesity-driven inflammation may explain increased risk and mortality of breast cancer with T2D reported in the epidemiology literature. Therapeutic approaches to target inflammation in both T2D and cancer have so far fallen short of the expected improvements in disease pathogenesis or outcomes. The targeting of epigenetic regulators of cytokine transcription and cytokine signaling offers one promising, untapped approach to treating diseases driven by inflammation. Recent work has deeply implicated the Bromodomain and Extra-Terminal domain (BET) proteins, which are acetylated histone “readers”, in epigenetic regulation of inflammation. This review focuses on inflammation associated with T2D and breast cancer, and the possibility of targeting BET proteins as an approach to regulating inflammation in the clinic. Understanding inflammation in the context of BET protein regulation may provide a basis for designing promising therapeutics for T2D and breast cancer.

Original language	English
Pages (from-to)	231-243
Number of pages	13
Journal	Cellular and Molecular Life Sciences
Volume	74
Issue number	2
DOIs	https://doi.org/10.1007/s00018-016-2320-0
State	Published - Aug 4 2016

Bibliographical note

Funding Information:
This work was supported by Grants from the National Institutes of Health: R56 DK090455 and U01 CA182898 (GVD); R21 DK089270 (BSN); Hematology Training Program T32 HL007501; and Immunology Training Program T32 AI089673.

Publisher Copyright:
© 2016, Springer International Publishing.

Keywords

Chromatin reader
Metabolism

ASJC Scopus subject areas

Molecular Medicine
Molecular Biology
Pharmacology
Cellular and Molecular Neuroscience
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00018-016-2320-0

Cite this

@article{d5403499af5c44b389bed229734292ad,

title = "BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer",

abstract = "Chronic inflammation drives pathologies associated with type 2 diabetes (T2D) and breast cancer. Obesity-driven inflammation may explain increased risk and mortality of breast cancer with T2D reported in the epidemiology literature. Therapeutic approaches to target inflammation in both T2D and cancer have so far fallen short of the expected improvements in disease pathogenesis or outcomes. The targeting of epigenetic regulators of cytokine transcription and cytokine signaling offers one promising, untapped approach to treating diseases driven by inflammation. Recent work has deeply implicated the Bromodomain and Extra-Terminal domain (BET) proteins, which are acetylated histone “readers”, in epigenetic regulation of inflammation. This review focuses on inflammation associated with T2D and breast cancer, and the possibility of targeting BET proteins as an approach to regulating inflammation in the clinic. Understanding inflammation in the context of BET protein regulation may provide a basis for designing promising therapeutics for T2D and breast cancer.",

keywords = "Chromatin reader, Metabolism",

author = "Nicholas, {Dequina A.} and Guillaume Andrieu and Strissel, {Katherine J.} and Nikolajczyk, {Barbara S.} and Denis, {Gerald V.}",

note = "Funding Information: This work was supported by Grants from the National Institutes of Health: R56 DK090455 and U01 CA182898 (GVD); R21 DK089270 (BSN); Hematology Training Program T32 HL007501; and Immunology Training Program T32 AI089673. Publisher Copyright: {\textcopyright} 2016, Springer International Publishing.",

year = "2016",

month = aug,

day = "4",

doi = "10.1007/s00018-016-2320-0",

language = "English",

volume = "74",

pages = "231--243",

number = "2",

}

TY - JOUR

T1 - BET bromodomain proteins and epigenetic regulation of inflammation

T2 - implications for type 2 diabetes and breast cancer

AU - Nicholas, Dequina A.

AU - Andrieu, Guillaume

AU - Strissel, Katherine J.

AU - Nikolajczyk, Barbara S.

AU - Denis, Gerald V.

N1 - Funding Information: This work was supported by Grants from the National Institutes of Health: R56 DK090455 and U01 CA182898 (GVD); R21 DK089270 (BSN); Hematology Training Program T32 HL007501; and Immunology Training Program T32 AI089673. Publisher Copyright: © 2016, Springer International Publishing.

PY - 2016/8/4

Y1 - 2016/8/4

N2 - Chronic inflammation drives pathologies associated with type 2 diabetes (T2D) and breast cancer. Obesity-driven inflammation may explain increased risk and mortality of breast cancer with T2D reported in the epidemiology literature. Therapeutic approaches to target inflammation in both T2D and cancer have so far fallen short of the expected improvements in disease pathogenesis or outcomes. The targeting of epigenetic regulators of cytokine transcription and cytokine signaling offers one promising, untapped approach to treating diseases driven by inflammation. Recent work has deeply implicated the Bromodomain and Extra-Terminal domain (BET) proteins, which are acetylated histone “readers”, in epigenetic regulation of inflammation. This review focuses on inflammation associated with T2D and breast cancer, and the possibility of targeting BET proteins as an approach to regulating inflammation in the clinic. Understanding inflammation in the context of BET protein regulation may provide a basis for designing promising therapeutics for T2D and breast cancer.

AB - Chronic inflammation drives pathologies associated with type 2 diabetes (T2D) and breast cancer. Obesity-driven inflammation may explain increased risk and mortality of breast cancer with T2D reported in the epidemiology literature. Therapeutic approaches to target inflammation in both T2D and cancer have so far fallen short of the expected improvements in disease pathogenesis or outcomes. The targeting of epigenetic regulators of cytokine transcription and cytokine signaling offers one promising, untapped approach to treating diseases driven by inflammation. Recent work has deeply implicated the Bromodomain and Extra-Terminal domain (BET) proteins, which are acetylated histone “readers”, in epigenetic regulation of inflammation. This review focuses on inflammation associated with T2D and breast cancer, and the possibility of targeting BET proteins as an approach to regulating inflammation in the clinic. Understanding inflammation in the context of BET protein regulation may provide a basis for designing promising therapeutics for T2D and breast cancer.

KW - Chromatin reader

KW - Metabolism

UR - http://www.scopus.com/inward/record.url?scp=84982883579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982883579&partnerID=8YFLogxK

U2 - 10.1007/s00018-016-2320-0

DO - 10.1007/s00018-016-2320-0

M3 - Review article

C2 - 27491296

AN - SCOPUS:84982883579

VL - 74

SP - 231

EP - 243

IS - 2

ER -

BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this